Sia Review

April 2026

Sia Review (April 2026)

DuraSorb® Monofilament Mesh,100% bioresorbable scaffold engineered from trusted polydioxanone (PDO) material to address limitations in current soft tissue reinforcement options, support natural healing, and minimize risk of infection.1-5* *Performance from pre-clinical investigation. Pre-clinical results may not be indicative of clinical results.

$13MRevenue

81Employees

-2%Growth

$13M

Revenue

81

Employees

-2%

Growth

Visit

Estimated Revenue

$13M

Total Funding

$3M

Total Employees

81

Employee Growth

-2%

Industry

Biotech

Location

Chicago, United States

About

DuraSorb® Monofilament Mesh,100% bioresorbable scaffold engineered from trusted polydioxanone (PDO) material to address limitations in current soft tissue reinforcement options, support natural healing, and minimize risk of infection.1-5* *Performance from pre-clinical investigation. Pre-clinical results may not be indicative of clinical results.

Global Rank

N/A

What is Sia's Revenue?

Sia's estimated revenue is $13M.

What does Sia do?

DuraSorb® Monofilament Mesh,100% bioresorbable scaffold engineered from trusted polydioxanone (PDO) material to address limitations in current soft tissue reinforcement options, support natural healing, and minimize risk of infection.1-5* *Performance from pre-clinical investigation. Pre-clinical results may not be indicative of clinical results.

Company	Revenue	Employees	Growth	Funding
NeuroLux	$2.6M	17	-6.7%	N/A
AMNIOCHOR	$0.9M	6	0.0%	N/A
Artemis Bio-Solutions	$2.5M	16	0.0%	N/A
Advanced Heathcare	$2.8M	18	66.7%	N/A
Proteintech	$38.4M	248	18.0%	N/A
Back of the Yards algae sciences (BYAS)	$2.0M	13	-21.4%	N/A
Paradise Genomics	$1.4M	9	-30.0%	N/A
BIOLIFE4D	$1.4M	9	0.0%	N/A
BiomeSense	$2.5M	16	8.3%	N/A
Vision Share	$2.3M	15	140.0%	N/A